To determine the value of transesophageal ultrasound in the assessment of cardiac valve prostheses, 14 patients with clinically suspected mitral prosthesis malfunction were studied by transthoracic and transesophageal two-dimensional imaging as well as by color Doppler flow velocity mapping (color Doppler). Patients underwent left ventricular angiography (n = 13), surgery (n =11), or both angiography and surgery (n = 10). Nine patients had only mitral valve replacement, four patients had both mitral and aortic valve replacement, and one patient had mitral, aortic, and tricuspid valve replacement. There were 16 biological and four mechanical prostheses. The degree of mitral regurgitation was graded by both transthoracic and transesophageal color Doppler according to the area of the regurgitant jet visualized and was compared with a three-point classification of mitral regurgitation by left ventricular angiography judged by observers blinded to the echocardiographic results. All transesophageal studies were performed without complication and were well tolerated. The pathological morphology of the mitral prosthesis was additionally or more clearly visualized by transesophageal twodimensional imaging and subsequently proven at surgery in three patients with flail leaflets and one patient with a vegetation compared with images obtained by the transthoracic approach. Valvular regurgitation was graded by the transthoracic approach as absent in four patients, mild in two patients, moderate in five patients, and severe in only three patients. The transesophageal assessment showed absence of mitral regurgitation in two patients, moderate regurgitation in two patients, and severe regurgitation in 10 patients. Left ventricular angiography done in 13 of the 14 patients revealed no regurgitation in two patients, mild regurgitation in one patient, moderate regurgitation in one patient, and severe mitral regurgitation in nine patients. This corresponded to the grading by transesophageal echocardiography in 12 of the 13 patients with the 13th patient graded as mild regurgitation by angiography and moderate regurgitation by transesophageal echocardiography. We conclude that in patients with biological mitral prosthesis malfunction, transesophageal two-dimensional imaging, as well as color Doppler, can provide reliable diagnostic information beyond that available from the transthoracic approach with the degree of mitral regurgitation corresponding to that found on left ventricular angiography. (Circulation 1988;78:848-855) TNhe potential value of transthoracic twoeven with advanced ultrasound equipment in obese dimensional and Doppler echocardiography and emphysematous patients, as well as in patients in the assessment of prosthetic heart valves with chest deformities and in the early postoperahas been well established. [1] [2] [3] [4] However, accurate tive period. Even in apparently high-quality recorddiagnosis of prosthesis malfunction may be difficult ings, the ultrasound beam is attenuated by the material of most prostheses.5 This fact compro-
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TNhe potential value of transthoracic twoeven with advanced ultrasound equipment in obese dimensional and Doppler echocardiography and emphysematous patients, as well as in patients in the assessment of prosthetic heart valves with chest deformities and in the early postoperahas been well established. [1] [2] [3] [4] 14) , all of whom complained of increasing fatigue and shortness of breath. In two patients (patients 3 and 13) with positive blood cultures, the echocardiographic study was done to assess possible endocarditis. Auscultation was within normal limits for each prosthesis in patient 13 but suggested mitral regurgitation in patient 3. In one patient (9) , the ultrasound examination was done because of newly developed severe heart failure. Only one of the 14 patients was mechanically ventilated at the time of the ultrasound examination.
Echocardiography
Equipment. Transthoracic and transesophageal two-dimensional and color Doppler flow velocity mapping (color Doppler) were obtained with a Hewlett-Packard ultrasonograph (Model 77020 AC, Andover, Massachusetts). The transthoracic studies were performed with a 2.5-or 3.5-MHz transducer with continuous, pulsed, and color Doppler capabilities. For the transesophageal studies, we used two-dimensional imaging and color Doppler from a 5-MHz transducer, which was mounted at the tip of a 14-mm diameter adult gastroscope (Model 21362A, Hewlett-Packard echoscope).
Examinations. All transthoracic examinations included standard parasternal, apical, and subcostal transducer positions. [10] [11] [12] [13] [14] , the sewing ring of the prosthesis was well visualized; however, the echo signal quality from within the prosthesis was poor, resulting in an incomplete visualization of the leaflets of the four biological prostheses (patients 11-14). example of a transthoracic and transesophageal color Doppler echocardiogram is shown in Figure 2 . Transesophageal echocardiography has been accepted slowly in the United States, although it is widely used in Northern Europe and Japan. This is especially true for applications in clinical cardiology and most likely is because of concern about discomfort and risk in conscious patients. There is no doubt that transesophageal ultrasound is more unpleasant for the patient than the transthoracic approach and it may not be completely free of risk. In our experience (70 patients studied), the pharyngeal passage causes some discomfort, but in the hands of physicians who are familiar with this procedure, the introduction of the transducer usually can be done within approximately 30 seconds. The grading scheme used for the severity of mitral regurgitation was developed for transthoracic color Doppler.9,10 To our knowledge, such criteria have never been tested regarding transesophageal color Doppler. Because it is probable that the transesophageal approach is more sensitive than the transthoracic approach visualizing regurgitant jets, the criteria used for the classification of regurgitation may not be the same for both approaches.
Grading of Mitral Regurgitation
However, a comparison between the degree of mitral regurgitation judged from left ventricular angiography and that judged from the transesophageal color Doppler showed a good correspondence demonstrating the potential clinical usefulness of this grading scheme.
Comparing the area of the regurgitant jet to that of the left atrium is reported to improve the accuracy of grading the degree of mitral regurgitation versus angiography16; however, with transesophageal ultrasound, it is extremely difficult to visualize the entire left atrium within one frame.
Eleven of our 14 patients had bioprostheses in place so our results and conclusions may not be directly applicable to mechanical prostheses. Clinical Implications
In patients with suspected malfunction of a mitral bioprosthesis, transesophageal two-dimensional imaging, as well as color Doppler flow velocity mapping, can give valuable additional information beyond that available from the transthoracic approach. This is true not only for the underlying pathomorphology but also for the estimation of the severity of the regurgitant lesion. The improvement in diagnostic accuracy may allow one to avoid further diagnostic tests and facilitate optimal timing of surgical interventions. However, because transesophageal echocardiography causes some discomfort and is not completely free of risk, we have chosen to perform it only in selected patients (e.g., those in whom the transthoracic echocardiogram is of suboptimal quality or in whom the transthoracic study results do not correspond to the clinical findings and in whom the results of the transesophageal study might alter management decisions for the patient and/or his or her physician).
